Mast Cell Activation Syndrome
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
AS
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
AB ScienceMasitinib 4.5 mg/kg/day
Clinical Trials (1)
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
Start: Jul 2022Est. completion: Dec 2024
Phase 2Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space